Predict your next investment

Endologix company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
endologix.com

See what CB Insights has to offer

Founded Year

1992

Stage

Take Private | Alive

Total Raised

$177.5M

About Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Endologix Headquarter Location

2 Musick

Irvine, California, 92618,

United States

949-595-7200

Latest Endologix News

Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System

Sep 29, 2021

JAGUAR Study Evaluates ALTO Compared to Other Commercially Available EVAR Devices September 29, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif.--( BUSINESS WIRE )-- Endologix LLC , a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the company’s JAGUAR study to compare outcomes for the company’s ALTO® Abdominal Stent Graft System to other commercially available endovascular aneurysm repair (EVAR) devices for the treatment of abdominal aortic aneurysm (AAA). JAGUAR (ObJective Analysis to GaUge EVAR Outcomes Through Randomization in a Real-world Population) is a prospective, randomized, multi-center study that will enroll approximately 450 patients at up to 60 sites worldwide. The study is designed for at least 300 patients to be randomly allocated to the ALTO cohort and 150 to the comparator group. All patients will be followed through five years. Results from the study will be independently adjudicated by a third party. “The availability of compelling clinical evidence for EVAR devices is crucial for making informed treatment decisions and improving patient outcomes,” said Jean Panneton, MD, vascular surgeon with Sentara Vascular Specialists who treated the patient at Sentara Norfolk General Hospital. JAGUAR has two primary endpoints: a clinical endpoint and an imaging endpoint. The clinical endpoint is a composite of aneurysm-related complications and consists of freedom from device-related interventions, conversion to open surgery, Type I and III endoleaks, clinically significant device migration, aneurysm enlargement, occlusion, aneurysm rupture and aneurysm-related death. The imaging endpoint is related to proximal neck dilation over time and allows for early insight into mechanisms of graft failure. “Endologix is committed to investing in clinical evidence,” said Prof. Matt Thompson, chief medical officer of Endologix. “JAGUAR joins our LEOPARD study as the only two randomized clinical trials designed to evaluate comparative endograft performance. We believe that this real-world study will provide valuable insights to inform EVAR treatment decisions and improve patient outcomes.” About the ALTO Abdominal Stent Graft System Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients. ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive Adaptive Sealing Technology that molds in-situ to the patient’s specific aortic neck anatomy. About Endologix Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. These products are designed to treat a wide spectrum of vascular disease from abdominal aortic aneurysms to lower limb peripheral vascular disease. Excellent clinical outcomes will be achieved through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. Endologix’s abdominal aortic aneurysm (AAA) products are built on one of two platforms: Traditional minimally invasive endovascular aneurysm repair (EVAR) and endovascular aneurysm sealing (EVAS), which is investigational product. Endologix’s current commercial EVAR products include the AFX®2 device and the ALTO® Abdominal Stent Graft System. Endologix became a private company, wholly owned by Deerfield Management on Oct. 1, 2020. The company has offices and manufacturing sites in Irvine and Santa Rosa. To learn more about Endologix, please visit http://www.endologix.com/ . About Deerfield Management Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. For more information, please visit www.deerfield.com . Cautions Regarding Forward-Looking Statements Except for historical information contained herein, this press release contains forward-looking statements, including statements regarding the JAGUAR clinical trial. Forward looking statements are subject to risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. The forward-looking statements contained in this press release speak only as of the date of this press release and Endologix undertakes no obligation to update any forward-looking statements contained in this press release to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Endologix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Endologix is included in 2 Expert Collections, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

M

Medical Devices

899 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Endologix Patents

Endologix has filed 75 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Diseases of the aorta
  • Implants (medicine)
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/11/2019

9/28/2021

Dosage forms, Drug delivery devices, Polymers, Polymer chemistry, Polymerization reactions

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/11/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/28/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Dosage forms, Drug delivery devices, Polymers, Polymer chemistry, Polymerization reactions

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Endologix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Endologix Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.